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Introduction: Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc), has a
dramatic impact on prognosis and survival and is a leading cause of death.
Case description: A 40 years old female patient with difuse cutaneous SSc (dcSSc) presented with progressive
dyspnea, choking sensation, cough, abdominal distension, constipation and dysphagia to solids. The muscle power
was mildly reduced and multiple purpuric eruptions were present on the legs of variable sizes. The patient was
ANCA negative and had positive cryoglobulinemia. The hepatitis C virus test was positive and the skin biopsy
histopathology proved small vessel (leucocytoclastic) vasculitis. The modified Rodnan total skin score (MRSS) was 37.
There was deterioration of the pulmonary function tests and transesophageal echocardiography revealed PAH
(RVSP 60 mmHg). Sildenafil 50 mg/day resulted in a remarkable improvement of the dyspnea and Raynauds’ with a
significant improvement of the skin tightness as the MRSS became 22. The small vessel vasculitic rash remarkably
improved and the RVSP became 34 mmHg with a dramatic improvement of the PAH.
Discussion and evaluation: Sildenafil enhances vasodilatation, has antiproliferative effects and is effective in the
treatment of PAH. The remarkable improvement in the vasculitic skin lesions in this case after sildenafil is the
second report after the described dramatic improvement of small vessel vasculitis in a case with Takayasu arteritis.
The emerging trends make it necessary to exploit the full therapeutic potential of Sildenafil in scleroderma and PAH
with other extrapulmonary manifestations.
Conclusion: We report a very rare association of dcSSc with small vessel cryoglobulinemic vasculitis with a
remarkable improvement after sildenafil.
Keywords: Diffuse systemic sclerosis; Pulmonary hypertension; Cryoglobulinemic vasculitis; SildenafilCase presentation
A 40 year-old female with diffuse cutaneous systemic
sclerosis (dcSSc) for 3 years was admitted with palpita-
tions (24 hour Holter monitor showed ventricular ec-
topics). The patient was started on deltiazem 40 mg tid.
She developed progressive dyspnea, chocking sensation
and cough. The patient started to have abdominal dis-
tension, constipation and dysphagia to solids. Arthritis
of the knee started to occur with puffiness of the hands
and 10 minute morning stiffness and eventually she was* Correspondence: gheitamer@hotmail.com
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in any medium, provided the original work is punable to close a fist (Her sister has rheumatoid arth-
ritis). She started to feel proximal weakness on going
upstairs (grade 4 muscle power). The menstrual cycle
became irregular and there would be urgency of urine.
Laboratory investigations of the patient are shown in
Table 1. The case study conforms to the 1995 Helsinki
declaration and the patients gave an informed consent.
There was pitting edema of extremities, peripheral skin
tightness, coldness and Raynauds with sluggish peripheral
circulation. Skin tightness was increased as reflected by
the increased modified Rodnan total skin score (MRSS)n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Laboratory features of the diffuse cutaneous
systemic sclerosis patients with pulmonary hypertension































Anti-Ro (U/ml) Positive (28.2)




Hb: Hemoglobin, WBC: White blood cells count, CK: creatine kinase, LDH:
lactate dehydrogenase, ESR: Erythrocyte sedimentation rate, PT: prothrombin
time, INR: Inverse neutralization ratio, PTT: partial thromboplastin time,
LDL: low density lipoprotein, HDL: high density lipoprotein, AST: Aspartate
transaminase, ALT: alanine transaminase, SUA: serum uric acid, RBF:
rheumatoid factor, ANA: antinuclear antibody, ds DNA: double stranded
deoxyribonucleic acid, Scl-70: scleroderma 70, U1RNP: Uridine 1 ribonucleoprotein,
ANCA: antineutrophil cytoplasmic antibody, HCV: hepatitis C virus.
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sent on the legs and of variable sizes (Figure 1). Skin
biopsy histopathology proved small vessel (leucocytoclastic)vasculitis of the purpuric rash. The patient had a positive
hepatitis C virus (HCV) test by PCR and positive cryoglo-
bulinemia. The pulmonary function test was consistent
with a restrictive pattern with progressive deterioration
(FEV1 (58.2%), FVC (64.7%), DLCO (16.9%) and FEV1/
FVC (74.5%) compared to the results of her preceding
follow-up. Transesophageal echocardiography revealed
pulmonary hypertension (RVSP 60 mmHg), EF (63%)
with moderate pericardial effusion which were verified
by a non-contrast CT chest.
The patient was prescribed prednisolone 40 mg/day,
warfarin 3 mg/day, furosemide 20 mg with spirono-
lactone 100 mg, verapamil 120 mg/day. In addition, the
patient received a daily dose of omeprazole 40 mg, do-
mperidone 10 mg before the main meal, simethicone
chew tablets, calcium carbonate 500 mg and colchicines
0.5 mg twice daily for a month. There was slight im-
provement of the dyspnea and skin rash while all other
symptoms persisted. The ESR was reduced from 114 to
be 85 mm/1st hr.
One week later it was decided to add sildenafil 50 mg/
day with a remarkable improvement of the dyspnea and
Raynauds’ with a reduction of the peripheral edema
as well as a significant improvement of the skin tight-
ness as the MRSS became 22. The small vessel vascu-
litic rash remarkably improved (Figure). The pulmonary
function tests significantly improved: FEV1 77%, FVC
79.2%, DLCO 45.2%, FEV1/FVC 88.6. The echocardio-
graphy results were enhanced with an EF 73% and a re-
duction of the pericardial effusion. The RVSP became
34 mmHg with a dramatic improvement of the pulmon-
ary hypertension. The patient significantly improved
with a favorable clinical and functional outcome on the
regular follow ups for the following year.
Using a selective pulmonary vasodilator as sildenafil
contributes to the significant improvement of the clinical
conditions and pulmonary hemodynamics which benefits
patients with severe pulmonary hypertension resistant
to conventional therapy (Catapano-Minotti et al. 2008;
Shahin 2006). The pulmonary arterial hypertension as-
sociated with connective tissue disease is difficult to
manage, and has a poor prognosis. The PDE5 inhibitor
‘sildenafil’ enhances vasodilatation, has antiproliferative
effects, and is effective in the treatment of PAH (Badesch
et al. 2007). The vasculopathy associated with SSc is con-
sidered noninflammatory, yet frank vasculitis can compli-
cate it posing diagnostic and therapeutic challenges (Kao
and Weyand 2010).
We report a very rare association of dcSSc with small
vessel cryoglobulinemic vasculitis. It has been reported
that cryoglobulinemic vasculitis is rarely encountered in
SSc patients (Kao and Weyand 2010). The remarkable
improvement in the vasculitic skin lesions in this case
after sildenafil is the second report after the described
Figure 1 Purpuric skin rash (small vessel vasculitis) in a 40 year old female with diffuse cutaneous systemic sclerosis (dcSSc) and
pulmonary arterial hypertension (PAH) before (left) and after (right) treatment with sildenafil.
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with Takayasu arteritis (Uthman and Chaaban 2006).
The emerging trends make it necessary to exploit the
full therapeutic potential of this class of drugs ‘sildenafil’
in scleroderma and PAH with other extrapulmonary
manifestations.
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